Innovent Biologics company profile
Company profile
Innovent Biologics has 8,754 employees and is headquartered in Suzhou, China.
TYVYT, BYVASDA, SULINNO and Cyramza are among the brands through which Innovent Biologics, Inc. is best known, alongside Retsevmo and Jaypirca. The company works on antibody and protein medicines and takes them from discovery through manufacturing to sale, with therapies aimed at cancer, eye diseases, autoimmune conditions, heart disease and metabolic disorders. Besides its own portfolio, it distributes pharmaceutical products and provides consulting and research and development services. Its activity spans mainland China, the United States and Europe, as well as other international markets.
In the fiscal year ended December 2025, Innovent recorded revenue of CNY 13.0 billion, up 38.4% from the previous year, and net income of CNY 813.6 million. The company had 8,754 employees. It was founded in 2011 and is headquartered in Suzhou.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- 168 Dongping Street, 215123, Suzhou
- Employees
- 8,754
- Chief executive
- De-Chao Yu
- Founded
- 2011
- Fiscal year
- January - December
- Listing
- 1801 · HKEX
- Indices
- Hang Seng
- Currency
- HKD
- ISIN
- KYG4818G1010
- Website
- innoventbio.com
Innovent Biologics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Innovent Biologics1801 | Hong Kong SAR China | $17.82B | 8,754 | 7.4% | 105.4 |
| WuXi Biologics (Cayman)2269 | Hong Kong SAR China | $21.51B | 14,705 | 32.4% | 30.8 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $12.15B | 2,300 | -0.2% | — |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $11.65B | 22,838 | 28.2% | 34.2 |
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
